Seite 6 von 7
Oncology Partnering Deals ( Seite 6)
Diskussionsstatistik
Anzahl Beiträge: 64
Aufrufe gesamt: 8.805
Aufrufe heute: 11
Diskussionsnr.: 1.151.539
Aufrufe gesamt: 8.805
Aufrufe heute: 11
Diskussionsnr.: 1.151.539
WKN: 502090
ISIN: DE0005020903
Symbol: MDG
ISIN: DE0005020903
Symbol: MDG
| 1,21 |
|
-1,30 % -0,0160 |
Xetra (EUR), 25.05.12 | 17:36
Beitrag schreiben
Beliebteste Beiträge
Ansicht
- Umgekehrte Sortierung (neuste zuerst)
- Die letzten 30 Beiträge
- 500 Beiträge pro Seite
RichyBerlin
schrieb am 09.08.11 18:55:24
Beitrag Nr.51
(41.924.133)
Bewertung: 1 x
Antwort
Zitat
Präklinik!
Array adds $713M cancer drug pact with Genentech to deal roster
August 9, 2011 — 8:29am ET | By John Carroll
Array BioPharma ($ARRY) has added another high-profile pact to its roster of big-name collaborations. Genentech has stepped in with an upfront payment of $28 million and a promise of up to $685 million in milestones so it can snag the rights to develop ARRY-575, a preclinical ChK-1 program that will be combined with a similar program of Genentech's and pushed into Phase I.
Genentech plans to match ARRY-575 with another Phase I compound, RG7602 or GDC-0475. Genentech will be responsible for the development costs and is also committed to a double-digit royalty stream on the early-stage program...
http://www.fiercebiotech.com/story/array-adds-713m-cancer-dr…
Array adds $713M cancer drug pact with Genentech to deal roster
August 9, 2011 — 8:29am ET | By John Carroll
Array BioPharma ($ARRY) has added another high-profile pact to its roster of big-name collaborations. Genentech has stepped in with an upfront payment of $28 million and a promise of up to $685 million in milestones so it can snag the rights to develop ARRY-575, a preclinical ChK-1 program that will be combined with a similar program of Genentech's and pushed into Phase I.
Genentech plans to match ARRY-575 with another Phase I compound, RG7602 or GDC-0475. Genentech will be responsible for the development costs and is also committed to a double-digit royalty stream on the early-stage program...
http://www.fiercebiotech.com/story/array-adds-713m-cancer-dr…
RichyBerlin
schrieb am 16.11.11 10:49:18
Beitrag Nr.52
(42.356.990)
Bewertung: 2 x
Antwort
Zitat
Nicht Onkologie, aber Impfstoff-Deals betreffen uns ja genauso;
Und der hier ist wirklich heftig.
Curevac Tübingen (eine von den Hopp/Bohlen-Firmen) & Sanofi-Pasteur
http://www.curevac.de/
"...Für jeden einzelnen Impfstoffkandidaten kann Curevac bis zu 101,5 Millionen Euro Vorauszahlungen sowie Forschungs- und Entwicklungsgelder abrufen. Handelt es sich um einen Krankheitserreger der sowohl vorbeugend als auch therapeutisch bekämpft wird, erhöht sich die Summe auf maximal 150,5 Millionen Euro. Hinzu kommen Lizenzgebühren bei Verkäufen von Impfstoffen, die auf der RNA-Technologie basieren..."
Das Ganze mit 33Mio.$ unterstützt vom amerikanischen DARPA
http://www.transkript.de/wirtschaft/wirtschaftsartikel/?tx_t…
"..Finanziert wird dieses von der amerikanischen Defense Advanced Research Projects Agency (DARPA). Diese Behörde des US-Verteidigungsministeriums, die unter anderem Wegbereiter des Internet und des Global Positioning Systems (GPS) war, sichert sich mit der Unterstützung von Grundlagenforschung den Zugriff auf innovative Technologien. Für die Finanzierung in Höhe von 33,1 Millionen Dollar (24 Millionen Euro) erhält die DARPA Anrechte zur Nutzung der Technologie..."
--
Unsere Kooperation mit Sanofi ist ja 2006/2007 im Sande verlaufen, soweit ich weiss
Kommentare bitte wie immer im normalen Thread. Danke
Und der hier ist wirklich heftig.
Curevac Tübingen (eine von den Hopp/Bohlen-Firmen) & Sanofi-Pasteur
http://www.curevac.de/
"...Für jeden einzelnen Impfstoffkandidaten kann Curevac bis zu 101,5 Millionen Euro Vorauszahlungen sowie Forschungs- und Entwicklungsgelder abrufen. Handelt es sich um einen Krankheitserreger der sowohl vorbeugend als auch therapeutisch bekämpft wird, erhöht sich die Summe auf maximal 150,5 Millionen Euro. Hinzu kommen Lizenzgebühren bei Verkäufen von Impfstoffen, die auf der RNA-Technologie basieren..."
Das Ganze mit 33Mio.$ unterstützt vom amerikanischen DARPA
http://www.transkript.de/wirtschaft/wirtschaftsartikel/?tx_t…
"..Finanziert wird dieses von der amerikanischen Defense Advanced Research Projects Agency (DARPA). Diese Behörde des US-Verteidigungsministeriums, die unter anderem Wegbereiter des Internet und des Global Positioning Systems (GPS) war, sichert sich mit der Unterstützung von Grundlagenforschung den Zugriff auf innovative Technologien. Für die Finanzierung in Höhe von 33,1 Millionen Dollar (24 Millionen Euro) erhält die DARPA Anrechte zur Nutzung der Technologie..."
--
Unsere Kooperation mit Sanofi ist ja 2006/2007 im Sande verlaufen, soweit ich weiss
Kommentare bitte wie immer im normalen Thread. Danke
RichyBerlin
schrieb am 05.01.12 19:11:43
Beitrag Nr.53
(42.556.100)
Bewertung: 1 x
Antwort
Zitat
Fast-growing Forma grabs $815M cancer discovery deal with
Boehringer
January 5, 2012 — 8:44am ET | By John Carroll
http://www.fiercebiotech.com/story/fast-growing-forma-grabs-…
Forma Therapeutics has nabbed an $815 million deal--$65 million of that in an upfront payment and the rest in pre-commercial milestones--to direct its growing drug discovery engine to new small molecule cancer therapeutics for Boehringer Ingelheim.
The pact marks another coup for Forma, a 2011 Fierce 15 company which has built up an extensive R&D operation designed to serve up new programs to a hungry set of biopharma companies around the globe. In this case, Forma plans to focus on multiple oncology targets over a four-year period. And they've set out to crack some tough cancer cases.
January 5, 2012 — 8:44am ET | By John Carroll
http://www.fiercebiotech.com/story/fast-growing-forma-grabs-…
Forma Therapeutics has nabbed an $815 million deal--$65 million of that in an upfront payment and the rest in pre-commercial milestones--to direct its growing drug discovery engine to new small molecule cancer therapeutics for Boehringer Ingelheim.
The pact marks another coup for Forma, a 2011 Fierce 15 company which has built up an extensive R&D operation designed to serve up new programs to a hungry set of biopharma companies around the globe. In this case, Forma plans to focus on multiple oncology targets over a four-year period. And they've set out to crack some tough cancer cases.
RichyBerlin
schrieb am 10.01.12 19:08:18
Beitrag Nr.54
(42.575.330)
Bewertung: 1 x
Antwort
Zitat
und nochmal Forma, wie vor ein paar Tagen (s.Posting
vorher)Forma scores another Big Pharma deal in $700M J&J cancer pact
January 10, 2012 — 9:43am ET | By John Carroll
Just days after inking an $815 million cancer drug discovery pact with Boehringer Ingelheim, Forma Therapeutics agreed to put its fast-growing small molecule ops to work for J&J's Janssen in a $700 million deal. This new pact, which focuses on tumor metabolism, also allows Forma to hang on to the North American commercial rights on one of the programs it develops--adding some long-term upside for the biotech. The announcement did not reveal how much Janssen is paying upfront...
http://www.fiercebiotech.com/story/forma-scores-another-big-…
borsalin
schrieb am 26.01.12 18:00:33
Beitrag Nr.55
(42.653.253)
Bewertung: 1 x
Antwort
Zitat
http://www.deraktionaer.de/aktien-usa/biotech-uebernahmewahn…
Amgen wird den Micromet-Aktionären elf Dollar je Aktie zahlen. Damit beläuft sich das Transaktionsvolumen auf 1,15 Milliarden Dollar. Das Micromet-Management hat dem Deal bereits zugestimmt
Amgen wird den Micromet-Aktionären elf Dollar je Aktie zahlen. Damit beläuft sich das Transaktionsvolumen auf 1,15 Milliarden Dollar. Das Micromet-Management hat dem Deal bereits zugestimmt
Steven-35
schrieb am 26.01.12 19:22:24
Beitrag Nr.56
(42.653.813)
Antwort
Zitat
hmmmm, Micronet war im Tief bei 0,85 Doller ( vor ca. 4 Jahren )
und jetzt Übernahme zu 11 Dollar. Naja,Medigene war kürzlich auch
bei 0,85.............
RichyBerlin
schrieb am 27.01.12 10:47:55
Beitrag Nr.57
(42.656.482)
Bewertung: 1 x
Antwort
Zitat
Celgene snaps up Avila Therapeutics in $925M buyout
January 26, 2012 — 8:15am ET | By John Carroll
In less than five years Avila Therapeutics nailed down a reputation as an exciting developer of covalent drugs, with a lead Btk inhibitor for cancer garnering attention at a very early stage of development. Today it turned that excitement into a $925 million buyout deal with Celgene ($CELG), with $350 million of that coming in cash.
The jewel in Avila's crown is AVL-292, a Btk inhibitor now in Phase I. The dealmakers involved in the buyout snagged a $195 million commitment for milestones leading up to a potential approval for that program. And Celgene will add the Avilomics platform to its R&D division, with another $380 million in back-end payments for the progress of other drug candidates that spring off the platform.
The Bedford, MA-based biotech was named a Fierce 15 company back in 2010, not long after the company garnered its last venture round of $30 million. Avila has been recognized for its novel approach to protein silencing, with much of the attention centered on its lead therapy for B cell cancers. The developer also has two candidates for hepatitis C--AVL-181 and AVL-192 targeting the NS3 protein--believing that its ability to create better bonds can deliver a best-in-class drug for one of the world's hottest disease categories...
http://www.fiercebiotech.com/story/celgene-snaps-avila-thera…
(Avila, siehe auch Beiträge #39 und #48)
--
Steven-35, hier bitte nicht mehr kommentieren. Hier werden nur die Deals gesammelt.
Kommentare bitte im anderen Thread, thanx
http://www.wallstreet-online.de/diskussion/1141290-neustebei…
January 26, 2012 — 8:15am ET | By John Carroll
In less than five years Avila Therapeutics nailed down a reputation as an exciting developer of covalent drugs, with a lead Btk inhibitor for cancer garnering attention at a very early stage of development. Today it turned that excitement into a $925 million buyout deal with Celgene ($CELG), with $350 million of that coming in cash.
The jewel in Avila's crown is AVL-292, a Btk inhibitor now in Phase I. The dealmakers involved in the buyout snagged a $195 million commitment for milestones leading up to a potential approval for that program. And Celgene will add the Avilomics platform to its R&D division, with another $380 million in back-end payments for the progress of other drug candidates that spring off the platform.
The Bedford, MA-based biotech was named a Fierce 15 company back in 2010, not long after the company garnered its last venture round of $30 million. Avila has been recognized for its novel approach to protein silencing, with much of the attention centered on its lead therapy for B cell cancers. The developer also has two candidates for hepatitis C--AVL-181 and AVL-192 targeting the NS3 protein--believing that its ability to create better bonds can deliver a best-in-class drug for one of the world's hottest disease categories...
http://www.fiercebiotech.com/story/celgene-snaps-avila-thera…
(Avila, siehe auch Beiträge #39 und #48)
--
Steven-35, hier bitte nicht mehr kommentieren. Hier werden nur die Deals gesammelt.
Kommentare bitte im anderen Thread, thanx
http://www.wallstreet-online.de/diskussion/1141290-neustebei…
RichyBerlin
schrieb am 04.02.12 09:20:23
Beitrag Nr.58
(42.698.887)
Bewertung: 1 x
Antwort
Zitat
Threshold, Merck KGaA strike $525M licensing deal for promising
cancer drug
February 3, 2012 — 6:56am ET | By John Carroll
The dealmakers at South San Francisco-based Threshold Pharmaceuticals ($THLD) have crafted a $525 million licensing pact with Merck KGaA covering its late-stage cancer drug TH-302. Threshold snagged a $25 million upfront, a promise of $35 million in near-term paydays and a $20 million reward if upcoming pancreatic cancer data come in positive. And the biotech holds on to co-promotion rights in the United States.
In its release, Threshold outlined a total of $280 million in regulatory and development milestones and $245 million in milestones based on sales.
"The addition of TH-302 to our pipeline provides an important opportunity in several different tumor types to expand our oncology development program," said Susan Jane Herbert, who's in charge of business development and strategy at Merck Serono. "Given the fact that pancreatic cancer is a very difficult to treat indication, successful Phase II results could represent important upside for our company."
Threshold is all about TH-302. The biotech has 8 clinical trials underway involving the treatment.
In addition to the Phase II pancreatic cancer study,...
http://www.fiercebiotech.com/story/threshold-merck-kgaa-stri…
February 3, 2012 — 6:56am ET | By John Carroll
The dealmakers at South San Francisco-based Threshold Pharmaceuticals ($THLD) have crafted a $525 million licensing pact with Merck KGaA covering its late-stage cancer drug TH-302. Threshold snagged a $25 million upfront, a promise of $35 million in near-term paydays and a $20 million reward if upcoming pancreatic cancer data come in positive. And the biotech holds on to co-promotion rights in the United States.
In its release, Threshold outlined a total of $280 million in regulatory and development milestones and $245 million in milestones based on sales.
"The addition of TH-302 to our pipeline provides an important opportunity in several different tumor types to expand our oncology development program," said Susan Jane Herbert, who's in charge of business development and strategy at Merck Serono. "Given the fact that pancreatic cancer is a very difficult to treat indication, successful Phase II results could represent important upside for our company."
Threshold is all about TH-302. The biotech has 8 clinical trials underway involving the treatment.
In addition to the Phase II pancreatic cancer study,...
http://www.fiercebiotech.com/story/threshold-merck-kgaa-stri…
borsalin
schrieb am 05.02.12 10:12:52
Beitrag Nr.59
(42.701.061)
Antwort
Zitat
Wann endlich meldet ein deutsches Biotechunternehmen den nächsten
längst fälligen Deal?
übrigens
http://www.finanznachrichten.de/nachrichten-2012-02/22625947…
Pharma hat immer früher ihre Fühler (Geld) in der Forschung drin
hier am Beispiel Forschung an der der Eidgenössischen Technischen Hochschule in Zürich
übrigens
http://www.finanznachrichten.de/nachrichten-2012-02/22625947…
Pharma hat immer früher ihre Fühler (Geld) in der Forschung drin
hier am Beispiel Forschung an der der Eidgenössischen Technischen Hochschule in Zürich
RichyBerlin
schrieb am 29.02.12 19:41:20
Beitrag Nr.60
(42.828.665)
Bewertung: 1 x
Antwort
Zitat
Dainippon bags Boston Biomedical and cancer stem cell tech in
$2.6B buyout
February 29, 2012 — 7:35am ET | By John Carroll
Boston Biomedical's focus on targeting cancer stem cells has paid off. Japan's Dainippon Sumitomo has snapped up the biotech for $200 million down, $540 million in development milestones for its two clinical-stage programs and close to $1.9 billion in commercial milestones, provided the drugs can achieve mega-blockbuster status.
In exchange for the cash and the promise of biobucks to come, Dainippon gets BBI608 and BBI503 and a new subsidiary in the U.S. which will spearhead its expansion in the cancer drug R&D field. The pharma company boasts that the two drugs are "likely to become the first anticancer drugs in the world targeting cancer stem cells." BBI608 is being prepped for a Phase III clinical trial for colorectal cancer in North America and in Phase Ib and II clinical trials for various solid tumors. BBI503 is in Phase I clinical trial for patients with various advanced solid tumors in North America....
http://www.fiercebiotech.com/story/dainippon-bags-boston-bio…
---
Oral - RA :
Abbott's deal-team delivers $1.35B Galapagos RA pact
February 29, 2012 — 9:19am ET | By John Carroll
Still wheeling and dealing as it lays the foundation for an independent pharma operation, Abbott ($ABT) today revealed that it is paying Belgian biotech Galapagos $150 million upfront to license in a promising oral treatment for rheumatoid arthritis. And it will pony up an additional $200 million if Galapagos can deliver positive Phase II data, along with a billion dollars in potential milestones.
The object of Abbott's affection is GLPG0634, a JAK1 inhibitor that Galapagos has been developing for RA and other autoimmune diseases. The JAK, or Janus kinases, are a group of enzymes responsible for triggering autoimmune diseases.
"We are excited to continue the Phase II trials and expect to deliver to Abbott a complete Phase II package in 2014," .....
http://www.fiercebiotech.com/story/abbotts-deal-team-deliver…
February 29, 2012 — 7:35am ET | By John Carroll
Boston Biomedical's focus on targeting cancer stem cells has paid off. Japan's Dainippon Sumitomo has snapped up the biotech for $200 million down, $540 million in development milestones for its two clinical-stage programs and close to $1.9 billion in commercial milestones, provided the drugs can achieve mega-blockbuster status.
In exchange for the cash and the promise of biobucks to come, Dainippon gets BBI608 and BBI503 and a new subsidiary in the U.S. which will spearhead its expansion in the cancer drug R&D field. The pharma company boasts that the two drugs are "likely to become the first anticancer drugs in the world targeting cancer stem cells." BBI608 is being prepped for a Phase III clinical trial for colorectal cancer in North America and in Phase Ib and II clinical trials for various solid tumors. BBI503 is in Phase I clinical trial for patients with various advanced solid tumors in North America....
http://www.fiercebiotech.com/story/dainippon-bags-boston-bio…
---
Oral - RA :
Abbott's deal-team delivers $1.35B Galapagos RA pact
February 29, 2012 — 9:19am ET | By John Carroll
Still wheeling and dealing as it lays the foundation for an independent pharma operation, Abbott ($ABT) today revealed that it is paying Belgian biotech Galapagos $150 million upfront to license in a promising oral treatment for rheumatoid arthritis. And it will pony up an additional $200 million if Galapagos can deliver positive Phase II data, along with a billion dollars in potential milestones.
The object of Abbott's affection is GLPG0634, a JAK1 inhibitor that Galapagos has been developing for RA and other autoimmune diseases. The JAK, or Janus kinases, are a group of enzymes responsible for triggering autoimmune diseases.
"We are excited to continue the Phase II trials and expect to deliver to Abbott a complete Phase II package in 2014," .....
http://www.fiercebiotech.com/story/abbotts-deal-team-deliver…
[ Seite: 1, 2, 3 … 5, 6, 7, neuster Beitrag ]
| Zeit | Titel |
|---|---|
08:03 | |
11.05. | |
11.05. | |
11.05. | |
07.05. | |
07.05. | |
07.05. | |
07.05. | |
04.05. | |
04.05. |
| Zeit | Titel |
|---|---|
19:14 | |
11.05. | |
01.05. | |
24.04. | |
14.02. | |
19.01. | |
03.08. | |
15.07. |
Geben Sie Ihre Bewertung zu dieser Seite: sehr gut
1
2
3
4
5
6 schlecht
Problem melden?
Impressum | Werben | Jobs | Allgemeine Nutzungsbestimmungen | Disclaimer | Archiv | Sitemap | Hilfe | Kontakt | RSS |
wallstreet:online AG | Börsen- & Finanzwidgets für Ihre Homepage |
Kurse:
Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min.
Alle Angaben ohne Gewähr. Copyright © 1998-2012 wallstreet:online AG - Alle Rechte vorbehalten.